NCT04421599

Brief Summary

H1: Aspiration is not necessary for IM injections applied from the ventrogluteal region. H2: Aspiration procedure increases pain in IM injections applied from ventrogluteal region. H3: The duration of the aspiration procedure on IM injections applied from the ventrogluteal region is effective on pain.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
834

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2019

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 14, 2019

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

June 4, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 9, 2020

Completed
1 day until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 10, 2020

Completed
10 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 20, 2020

Completed
Last Updated

June 11, 2020

Status Verified

June 1, 2020

Enrollment Period

1.4 years

First QC Date

June 4, 2020

Last Update Submit

June 9, 2020

Conditions

Keywords

Ventrogluteal areaaspiration

Outcome Measures

Primary Outcomes (2)

  • Individual Introductory Information Form

    The content of the study was explained to the patients coming to the emergency room. Written informed consents were obtained in line with the "Individual Introductory Information Form" of the patients. Individual Introductory Information Form: This form includes questions such as the patient's application group, diagnosis, age, gender, height, weight, and blood intake during aspiration in intramuscular injection. It is completed within the first 10-15 minutes of contact with the patient.

    15 minutes

  • Visual Analog Scale (VAS)

    Intramuscular injection was performed in accordance with the application group assigned to the patients who filled the Individual Introductory Information Form. The patients were not told which group they belonged to. A nurse who except the researcher who performed the application evaluated pain levels that patients feel during injection immediately after the intramuscular injection application, with a Visual Analog Scale. The minimum score that can be obtained from this scale is 0 and the maximum score is 10. A higher score indicates that the pain is more severe. This scale was applied in minutes 1-5 after intramuscular injection.

    5 minutes

Study Arms (3)

Experimental Group A

EXPERIMENTAL

Experimental Group A who were administered intramuscular injection during which aspiration lasted for 5-10 seconds.

Other: The Necessity of Aspiration

Control Group

NO INTERVENTION

Control Group who were administered intramuscular injection during which aspiration lasted for 1-2 seconds.

Experimental Group B

EXPERIMENTAL

Experimental Group B who were not administered aspiration during IM injection.

Other: The Necessity of Aspiration

Interventions

The patients who met the inclusion criteria and agreed to participate in the study were assigned to the Experimental Group A who were administered IM injection during which aspiration lasted for 5-10 seconds, to the Control Group who were administered IM injection during which aspiration lasted for 1-2 seconds, and to the Experimental Group B who were not administered IM injection according to the stratified block randomization list. The same "Intramuscular Injection Application Protocol" was applied while all the injections were administered.

Experimental Group AExperimental Group B

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient who came to the Emergency Service Care Unit for "Diclofenac Sodium" injection
  • Have no vision and hearing problems,
  • Who have no disease that may affect their perception of pain
  • Who can evaluate the "Visual Analog Scale" correctly, scoring 5 points or less from the VAS,
  • Body Mass Index is between 18.5-24.9 kg / m2,
  • Who do not have any discomfort in the extremities that will prevent them from taking the desired position,
  • No complications due to intramuscular injections such as abscess, infection, tissue necrosis and hematoma in the ventrogluteal region
  • No nodules or masses in the area

You may not qualify if:

  • Patients who refuse the injection are excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ege University Hospital

Izmir, Turkey (Türkiye)

Location

Related Publications (2)

  • Beyea SC, Nicoll LH. Administration of medications via the intramuscular route: an integrative review of the literature and research-based protocol for the procedure. Appl Nurs Res. 1995 Feb;8(1):23-33. doi: 10.1016/s0897-1897(95)80279-7.

    PMID: 7695353BACKGROUND
  • Baran L, Gunes U, Donmez H. Investigation of the Necessity of Aspiration During the Intramuscular Injection Administered in the Ventrogluteal Site and Its Effect on Pain: A Randomized Controlled Trial. Clin Nurs Res. 2023 May;32(4):821-829. doi: 10.1177/10547738221136470. Epub 2022 Dec 20.

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr.

Study Record Dates

First Submitted

June 4, 2020

First Posted

June 9, 2020

Study Start

January 14, 2019

Primary Completion

June 10, 2020

Study Completion

June 20, 2020

Last Updated

June 11, 2020

Record last verified: 2020-06

Data Sharing

IPD Sharing
Will not share

Locations